Safety, pharmacokinetic, and pharmacodynamic study of sibofimloc, a novel FimH blocker in patients with active Crohn's disease
2022
Reinisch, Walter | Hebuterne, Xavier | Buisson, Anthony | Schreiber, Stefan | Desreumaux, Pierre | Primas, Christian | Paillarse, Jean-Michel | Chevalier, Grégoire | Bonny, Christophe | Medizinische Universität Wien = Medical University of Vienna | Centre Hospitalier Universitaire de Nice | Service Hépato-Gastro-Entérologie | CHU Estaing | CHU Clermont-Ferrand-CHU Clermont-Ferrand-Pôle Spécialités médicales et chirurgicales | CHU Clermont-Ferrand | Infection Inflammation et Interaction Hôtes Pathogènes | Direction de la Recherche Clinique et de l’Innovation | CHU Clermont-Ferrand-CHU Clermont-Ferrand | Microbes, Intestin, Inflammation et Susceptibilité de l'Hôte | Institut National de la Santé et de la Recherche Médicale -Centre de Recherche en Nutrition Humaine d'Auvergne -Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement -Université Clermont Auvergne | University Medical Center of Schleswig–Holstein = Universitätsklinikum Schleswig-Holstein | Christian-Albrechts-Universität zu Kiel = Christian-Albrechts University of Kiel = Université Christian-Albrechts de Kiel | Centre Hospitalier Régional Universitaire | Institute for Translational Research in Inflammation - U | Institut National de la Santé et de la Recherche Médicale -Université de Lille-Centre Hospitalier Régional Universitaire | Enterome
Essai clinique - Phase I
Show more [+] Less [-]International audience
Show more [+] Less [-]English. Background and aim: Expression of FimH adhesin by invasive Escherichia coli in the gastrointestinal tract of patients with Crohn's disease (CD) facilitates binding to epithelial glycoproteins and release of pro-inflammatory cytokines. Sibofimloc is a first-in-class FimH blocker that showed little systemic absorption in healthy volunteers. The current study evaluated systemic absorption, safety, and effect on inflammatory biomarkers of sibofimloc in patients with CD.Methods: This was an open-label, multicenter phase 1b study in adults with active CD. In part 1, two patients received a single oral dose of 3000-mg sibofimloc followed by 1500 mg b.i.d. for 13 days. In part 2, six patients received 1500-mg sibofimloc b.i.d. for 13 days. Blood was drawn for pharmacokinetic and biomarker analysis, and stool was collected for biomarker and microbiome analysis.Results: Eight patients with active ileal or ileocolonic CD were enrolled into the study. Systemic sibofimloc exposure was low. Sibofimloc was well tolerated with only grade 1-2 events observed. Several pro-inflammatory biomarkers, including IL-1β, IL-6, IL-8, TNF-α, IFN-γ, and calprotectin, were decreased in stool by end of study.Conclusions: This first study of the novel FimH blocker, sibofimloc, in patients with active CD demonstrated minimal systemic exposure with good tolerance, while decreasing several inflammatory biomarkers. EudraCT number: 2017-003279-70.
Show more [+] Less [-]AGROVOC Keywords
Bibliographic information
This bibliographic record has been provided by National Institute for Agricultural Research